Why Is Boston Scientific Stock Soaring Wednesday?

Boston Scientific Corporation (NYSE:BSX) reported first-quarter 2026 revenues of $5.20 billion on Wednesday, slightly better than the consensus estimate of $5.17 billion, beating the management guidance of $5.22 billion-$5.31 billion.

Sales increased 11.6% on a reported basis, within the company’s guidance range of 10.5%-12%, and 9.4% on an operational and organic basis, within the company’s guidance range of 8.5%-10%.

The medical technology giant reported adjusted earnings of 80 cents, beating the consensus of 79 cents and the management guidance of 78-80 cents.

Boston Scientific Cardiovascular Segment Drives Double-Digit Growth

The revenue growth was driven primarily by strong performance in its Cardiovascular segment, which generated $3.503 billion in revenue with 11% organic growth.

The Cardiovascular business led performance, generating $3.50 billion (+11%), driven by Electrophysiology ($905 million, +22%), Watchman ($506 million, +19%), Interventional Cardiology & Vascular Therapies ($1.24 billion, +8%), and Interventional Oncology & Embolization ($268 million, +15%), partially offset by a decline in Cardiac Rhythm Management ($578 million, -3%).

The MedSurg segment delivered $1.70 billion (+6%), with growth in Neuromodulation ($318 million, +15%) and Endoscopy ($736 million, +7%), while Urology ($646 million) grew modestly at 1%.

Boston Scientific 2026 Outlook Cut On Softer Growth Expectations

The company lowered its fiscal 2026 adjusted earnings per share guidance from $3.43-$3.49 to $3.34-$3.41, below the Wall Street estimate of $3.45.

Boston Scientific forecasts net sales growth of approximately 7%-8.5% (prior 10.5%-11.5%) in 2026 on a reported basis, and 6.5%-8% (prior 10%-11%) organically.

The company also lowered 2026 sales guidance from $22.18 billion-$22.38 billion to $21.48 billion-$21.78 billion versus the consensus of $22.23 billion.

Q2 Guidance Signals Near-Term Pressure

The company expects net sales growth of approximately 5.5%-7.5% on a reported basis and 5%-7% organically in the second quarter of 2026, equivalent to sales of $5.34 billion-$5.44 billion, compared to the consensus of $5.55 billion.

The medtech giant expects adjusted earnings of 82-84 cents versus the consensus of 86 cents.

BSX Price Action: Boston Scientific shares were up 8.67% at $64.68 at the time of publication on Wednesday, according to Benzinga Pro data.

Image via Shutterstock